TY - JOUR
T1 - Fibrinogen catabolism in systemic lupus erythematosus
AU - Sergent, John S.
AU - Sherman, Raymond L.
AU - Al‐Mondhiry, Hamid
N1 - Copyright:
Copyright 2016 Elsevier B.V., All rights reserved.
PY - 1976
Y1 - 1976
N2 - Because there is mounting evidence that localized intravascular coagulation maycontribute to tissue injury following a variety of immunologic events, including immune complex diseases, fibrinogen catabolism was studied in patients with systemic lupus erythematosus to determine factors correlating with accelerated coagulation. 125I‐fibrinogen half‐life in controls was 80.1 ± 11 hours and the mean SLE half‐life was 60.5 ± 12. SLE patients in complete clinical remission had normal half‐lives, but patients with symptomatic clinical disease, including renal disease, had significantly reduced fibrinogen survival. Accelerated fibrinogen consumption also correlated with positive tests for anti‐DNA antibodies, but not with hypocomplementemia. These observations support the hypothesis that the coagulation system is activated in patients with immune complex diseases. Further studies are required to define the role, if any, that coagulation may play in causing tissue injury.
AB - Because there is mounting evidence that localized intravascular coagulation maycontribute to tissue injury following a variety of immunologic events, including immune complex diseases, fibrinogen catabolism was studied in patients with systemic lupus erythematosus to determine factors correlating with accelerated coagulation. 125I‐fibrinogen half‐life in controls was 80.1 ± 11 hours and the mean SLE half‐life was 60.5 ± 12. SLE patients in complete clinical remission had normal half‐lives, but patients with symptomatic clinical disease, including renal disease, had significantly reduced fibrinogen survival. Accelerated fibrinogen consumption also correlated with positive tests for anti‐DNA antibodies, but not with hypocomplementemia. These observations support the hypothesis that the coagulation system is activated in patients with immune complex diseases. Further studies are required to define the role, if any, that coagulation may play in causing tissue injury.
UR - http://www.scopus.com/inward/record.url?scp=0016931198&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=0016931198&partnerID=8YFLogxK
U2 - 10.1002/art.1780190211
DO - 10.1002/art.1780190211
M3 - Article
C2 - 1259800
AN - SCOPUS:0016931198
SN - 0004-3591
VL - 19
SP - 195
EP - 198
JO - Arthritis & Rheumatism
JF - Arthritis & Rheumatism
IS - 2
ER -